Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724666 | 0.86 | NLRP3 (0.52) | NLRP3PIK3CATLR7TLR8JAK2 | |
| SCHEMBL21732900 | 0.85 | GRM2 (0.34) | NLRP3GRM2TLR7TLR8JAK2 | |
| SCHEMBL21724477 | 0.84 | NLRP3 (0.49) | NLRP3TLR7TLR8JAK2 | |
| SCHEMBL21724254 | 0.83 | NLRP3 (0.49) | NLRP3TLR7TLR8JAK2 | |
| SCHEMBL21732873 | 0.81 | TLR7 (0.35) | NLRP3GRM2TLR7TLR8 | |
| SCHEMBL21724880 | 0.80 | NLRP3 (0.45) | NLRP3TLR7TLR8 | |
| SCHEMBL21724483 | 0.76 | NLRP3 (0.55) | NLRP3TLR7TLR8 | |
| SCHEMBL21732874 | 0.74 | TLR7 (0.33) | NLRP3GRM2TLR7TLR8JAK2 | |
| SCHEMBL26785470 | 0.72 | NLRP3 (0.47) | NLRP3PIK3CATLR7TLR8JAK2 | |
| SCHEMBL21733010 | 0.70 | JAK2 (0.42) | NLRP3TLR7TLR8JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201627-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-3837014-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20210308123-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-07 | — | — | US | disclosed |
| CN-113038989-A | Imidazo [4,5-C ] quinoline-derived NLRP3 modulators | 先天肿瘤免疫公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3837014-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020037091-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201627-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NLRP3 1/4885PIK3CA 2311/4885GRM2 1735/4885 |
| US-20210308123-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885PIK3CA 2311/4885GRM2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.